Zobrazeno 1 - 10
of 12
pro vyhledávání: '"Ann Marie Ptaszynski"'
Autor:
Farran L Peterson, Stacie Bell, Lance A Wollenberg, Coralee G. Mannila, Corson Donald T, Kevin Litwiler, Arrigo Alisha B, Ann Marie Ptaszynski, Courtney A Nugent
Publikováno v:
Clinical Pharmacology : Advances and Applications
Lance A Wollenberg,1 Donald T Corson,2,3 Courtney A Nugent,1 Farran L Peterson,1 Ann M Ptaszynski,1 Alisha Arrigo,2,3 Coralee G Mannila,2,3 Kevin S Litwiler,1 Stacie J Bell1,4 1Array BioPharma, Boulder, 2Array BioPharma, Longmont, CO, 3Avista Pharma
Autor:
Ann-Marie Ptaszynski, Philip Poortmans, Walter Van den Bogaert, Henk Struikmans, Harry Bartelink, Emmanuel van der Schueren, Marianne Pierart, Alain Fourquet, Laurence Collette, Jean-Claude Horiot
Publikováno v:
Acta Oncologica. 38:19-27
The influence of the radiation dose on local control and cosmetic outcome in breast-conserving treatment for breast cancer is investigated in EORTC trial 2288110882. In this study 50 Gy is administered to the whole breast, and the effect of an additi
Autor:
Hermann Einsele, Ann Marie Ptaszynski, Roger Aitchison, Albert Oriol, Robert Z. Orlowski, M Gyger, Philippe Moreau, Martin Kaiser, Meletios A. Dimopoulos, Brandi Hilder, Michel Delforge, Sagar Lonial
Publikováno v:
Journal of Clinical Oncology. 33:TPS8613-TPS8613
TPS8613 Background: An unmet medical need exists for patients (pts) with multiple myeloma (MM) whose disease has progressed despite prior exposure to immunomodulatory agents (IMiDs) and proteasome ...
Autor:
William I. Bensinger, Jeffrey A. Zonder, Donna M. Weber, Jonathan L. Kaufman, Brandi Hilder, Robert Z. Orlowski, Adam D. Cohen, Ajay K. Nooka, Ann Marie Ptaszynski, Walker Duncan H, Sagar Lonial, Jatin J. Shah, Selena A Rush
Publikováno v:
Blood. 122:285-285
Background The availability of multiple immunomodulators (IMiDs) and proteasome inhibitors (PIs) has resulted in improved outcomes for patients (pts) with multiple myeloma (MM). Pts refractory to these 2 classes of drugs have a poor prognosis and new
Autor:
Jonathan L. Kaufman, Steven Michael Burt, Joseph W. Fay, Ann Marie Ptaszynski, Kenneth Lau, Myo Htut, Selena A Rush, Ajai Chari, Andrzej Jakubowiak, Brandi Hilder, Jeffrey A. Zonder, Beverly Harrison
Publikováno v:
Blood. 122:1938-1938
Background ARRY-520 is a novel KSP inhibitor with encouraging activity in patients (pts) with RRMM. In preclinical models, the activity of ARRY-520 is synergistic with BTZ, providing a rationale to combine these drugs in the clinic. Methods ARRAY-520
Role of p38 MAPK and Tie2 in the Pathogenesis of MDS and Their Inhibition by Dual Inhibitor ARRY-614
Autor:
Jenn Garrus, David Chantry, Guillermo Garcia Manero, H. Jean Khoury, Mikkael A. Sekeres, LouAnn Cable, Grant Hogeland, Dan Weaver, Ann Marie Ptaszynski, Lara Maloney, Suzy Brown, Susan Rhodes, Rami S. Komrokji, Shannon L. Winski
Publikováno v:
Blood. 120:2825-2825
Abstract 2825 Myelodysplastic syndromes (MDS) are a heterogeneous collection of disorders characterized by dysfunctional bone marrow progenitors leading to peripheral cytopenias. The molecular mechanisms underlying MDS pathophysiology are unclear, bu
Autor:
Jonathan L. Kaufman, Muneer H. Abidi, Jeffrey A. Zonder, Brandi Hilder, Adam D. Cohen, Sheeba K. Thomas, William I. Bensinger, R. Donald Harvey, Sagar Lonial, Robert Z. Orlowski, Ann Marie Ptaszynski, Walker Duncan H, Jatin J. Shah
Publikováno v:
Blood. 120:449-449
Abstract 449 Background ARRY-520 is a kinesin spindle protein (KSP) inhibitor that arrests cells in mitosis and induces apoptosis due to degradation of the BCL2 family survival protein MCL-1. As previously reported, ARRY-520 has demonstrated single-a
Autor:
Kevin Litwiler, Walker Duncan H, Sharon Karan, Jeffrey A. Zonder, Donna M. Weber, Sheeba K. Thomas, Jonathan L. Kaufman, Adam D. Cohen, R. Donald Harvey, Ann Marie Ptaszynski, Jatin J. Shah, Brandi Hilder, Raymond Alexanian, Robert Z. Orlowski, Sagar Lonial
Publikováno v:
Blood. 118:1860-1860
Abstract 1860 Background: ARRY-520 is a potent, selective inhibitor of kinesin spindle protein (KSP, eg5) which is required for cell cycle progression through mitosis. Treatment with ARRY-520 arrests cells in mitosis with subsequent induction of apop
Autor:
Walker Duncan H, Jonathan L. Kaufman, Adam D. Cohen, Robert Z. Orlowski, Sheeba K. Thomas, Jeffrey A. Zonder, R. Donald Harvey, Donna M. Weber, Ann Marie Ptaszynski, William I Benzinger, Sagar Lonial, Brandi Hilder, Jatin J. Shah, Raymond Alexanian
Publikováno v:
Blood. 118:2935-2935
Abstract 2935 Background: ARRY-520 is a potent, selective inhibitor of kinesin spindle protein (KSP, eg5) which is required for cell cycle progression through mitosis. Treatment with ARRY-520 arrests cells in mitosis with subsequent onset of apoptosi
Autor:
Stacie Bell, Elias Jabbour, H. Jean Khoury, Rami S. Komrokji, Alan F. List, Maria Cielo Foudray, Jeffrey E. Lancet, Shannon L. Winski, Ann Marie Ptaszynski, Selena A Rush, Hagop M. Kantarjian, Lara Maloney, Guillermo Garcia-Manero
Publikováno v:
Blood. 118:118-118
Abstract 118 Background: Myelodysplastic syndromes (MDS) are characterized by excess elaboration of myelosuppressive cytokines contributing to increased apoptotic loss of hematopoietic precursors, the hallmark of lower-risk MDS. p38a MAP kinase (MAPK